Results 31 to 40 of about 268,148 (374)

PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome

NeuroImage, 2021
Introduction: Adults with Down syndrome (DS) are predisposed to Alzheimer's disease (AD) and reveal early amyloid beta (Aβ) pathology in the brain. Positron emission tomography (PET) provides an in vivo measure of Aβ throughout the AD continuum.
Matthew D. Zammit, Dana L. Tudorascu, Charles M. Laymon, Sigan L. Hartley, Shahid H. Zaman, Beau M. Ances, Sterling C. Johnson, Charles K. Stone, Chester A. Mathis, William E. Klunk, Ann D. Cohen, Benjamin L. Handen, Bradley T. Christian   +12 more
doaj   +1 more source

Cerebrospinal fluid Aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer’s disease [PDF]

, 2016
Background: Decreased concentrations of amyloid-β 1-42 (Aβ(42)) in cerebrospinal fluid (CSF) and increased retention of Aβ tracers in the brain on positron emission tomography (PET) are considered the earliest biomarkers of Alzheimer’s disease (AD ...
Blennow, Kaj, Eusebi, Paolo, Fagan, Anne M, Kornhuber, Johannes, Lewczuk, Piotr, Matzen, Anja, Molinuevo, Jose Luis, Morris, John C, Parnetti, Lucilla   +8 more
core   +3 more sources

Breaking the Cycle, Cholesterol Cycling, and Synapse Damage in Response to Amyloid-ß [PDF]

, 2017
Soluble amyloid-β (Aβ) oligomers, a key driver of pathogenesis in Alzheimer disease, bind to cellular prion proteins (PrPC) expressed on synaptosomes resulting in increased cholesterol concentrations, movement of cytoplasmic phospholipase A2 (cPLA2) to ...
Bate, C
core   +3 more sources

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

EMBO Molecular Medicine, 2020
In Alzheimer’s disease (AD), tau phosphorylation in the brain and its subsequent release into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease evolution.
M. Suárez‐Calvet, T. Karikari, N. Ashton, Juan Lantero Rodríguez, M. Milà-Alomà, J. Gispert, G. Salvadó, C. Minguillón, K. Fauria, M. Shekari, O. Grau-Rivera, E. Arenaza‐Urquijo, A. Sala-Vila, G. Sánchez-Benavides, J. González-de-Echávarri, Gwendlyn Kollmorgen, E. Stoops, E. Vanmechelen, H. Zetterberg, K. Blennow, J. Molinuevo, Annabella Beteta, R. Cacciaglia, Alba Cañas, C. Deulofeu, Irene Cumplido, Ruth Domínguez, Maria Emilio, C. Falcón, Sherezade Fuentes, Laura Hernández, Gema Huesa, J. Huguet, P. Marne, Tania Menchón, G. Operto, A. Polo, Sandra Pradas, Anna Soteras, M. Vilanova, N. Vilor-Tejedor   +40 more
semanticscholar   +1 more source

Aβ degradation—the inside story [PDF]

Frontiers in Aging Neuroscience, 2014
Two decades have passed since the discovery of the first proteases that degrade the amyloid β-protein (Aβ) (Roher et al., 1994; Turner et al., 2004), the primary constituent of the amyloid plaques that characterize Alzheimer disease (AD) (Selkoe, 2000).
openaire   +2 more sources

Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study

Aging Brain, 2022
Introduction: The typical spatial pattern of amyloid-β (Aβ) in diagnosed Alzheimer’s disease (AD) is that of a symmetrical hemispheric distribution. However, Aβ may be asymmetrically distributed in early stages of AD.
Pernille L. Kjeldsen, Peter Parbo, Kim V. Hansen, Joel F.A. Aanerud, Rola Ismail, Peter H. Nissen, Rikke B. Dalby, Malene F. Damholdt, Per Borghammer, David J. Brooks   +9 more
doaj   +1 more source

Oxidative Damages on the Alzheimer’s Related-Aβ Peptide Alters Its Ability to Assemble

Antioxidants, 2023
Oxidative stress that can lead to oxidation of the amyloid-β (Aβ) peptide is considered a key feature in Alzheimer’s disease (AD), influencing the ability of Aβ to assemble into β-sheet rich fibrils that are commonly found in senile plaques of AD ...
Clémence Cheignon, Fabrice Collin, Laurent Sabater, Christelle Hureau   +3 more
doaj   +1 more source

A resorcinarene for inhibition of Aβ fibrillation. [PDF]

, 2017
Amyloid-β peptides (Aβ) fibrillation is the hallmark of Alzheimer's disease (AD). However, it has been challenging to discover potent agents in order to inhibit Aβ fibrillation.
Han, Xu, Houk, KN, Leblanc, Roger M, Malagon, Andres, Park, Jiyong, Vargas, Edgar, Wang, Lingyu, Wikramanayake, Athula, Wu, Wei   +8 more
core   +1 more source

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

Science Advances, 2020
Aβ pathology may induce changes in soluble tau release and phosphorylation, which is later followed by tau aggregation. The links between β-amyloid (Aβ) and tau in Alzheimer’s disease are unclear. Cognitively unimpaired persons with signs of Aβ pathology
N. Mattsson‐Carlgren, E. Andersson, S. Janelidze, R. Ossenkoppele, P. Insel, O. Strandberg, H. Zetterberg, H. Rosen, G. Rabinovici, Xiyun Chai, K. Blennow, Jeffrey L. Dage, E. Stomrud, Ruben Smith, S. Palmqvist, O. Hansson   +15 more
semanticscholar   +1 more source

Differential Detection of Amyloid Aggregates in Old Animals Using Gold Nanorods by Computerized Tomography: A Pharmacokinetic and Bioaccumulation Study

International Journal of Nanomedicine, 2023
Pedro Jara-Guajardo,1,2 Francisco Morales-Zavala,1,2 Karen Bolaños,1– 3 Ernest Giralt,4,5 Eyleen Araya,2,6 Gerardo A Acosta,7,8 Fernando Albericio,5,7,9 Alejandra R Alvarez,10 Marcelo J Kogan1,2 1Departamento de Quimica Farmacologica y Toxicologica ...
Jara-Guajardo P, Morales-Zavala F, Bolaños K, Giralt E, Araya E, Acosta GA, Albericio F, Alvarez AR, Kogan MJ   +8 more
doaj